{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:55:10Z","timestamp":1762102510002,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00905","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T04:51:14Z","timestamp":1591246274000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan"],"prefix":"10.3389","volume":"10","author":[{"given":"Chiao-En","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan-Keng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Ting","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Fen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Yuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan-Wu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Juan","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Wen-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV CHECKMATE 511 trial","volume":"37","author":"Lebbe","year":"2019","journal-title":"J Clin Oncol."},{"key":"B7","first-page":"602","article-title":"Cutaneous melanoma: Taiwan experience and literature review","volume":"33","author":"Chang","year":"2010","journal-title":"Chang Gung Med J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/ajco.12670","article-title":"Sunrise in melanoma management: time to focus on melanoma burden in Asia","volume":"13","author":"Chang","year":"2017","journal-title":"Asia Pac J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1471-2407-11-85","article-title":"Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases","volume":"11","author":"Chi","year":"2011","journal-title":"Bmc Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"9655","DOI":"10.2147\/CMAR.S227837","article-title":"Sentinel lymph node biopsy was associated with favorable survival outcomes for patients with clinically node-negative Asian melanoma","volume":"11","author":"Chang","year":"2019","journal-title":"Cancer Manag Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jfma.2013.06.018","article-title":"Prognostic factors for Taiwanese patients with cutaneous melanoma undergoing sentinel lymph node biopsy","volume":"114","author":"Wu","year":"2015","journal-title":"J Formos Med Assoc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3389\/fonc.2019.01161","article-title":"The predictive value of tumor mutation burden on efficacy of immune checkpoint inhibitors in cancers: a systematic review and meta-analysis","volume":"9","author":"Wu","year":"2019","journal-title":"Front Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/cncr.30259","article-title":"The efficacy of anti-PD-1 agents in acral and mucosal melanoma","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer."},{"key":"B16","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1634\/theoncologist.2014-0468","article-title":"Clinical activity of ipilimumab in acral melanoma: a retrospective review","volume":"20","author":"Johnson","year":"2015","journal-title":"Oncologist."},{"key":"B17","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41416-018-0207-6","article-title":"Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006","volume":"119","author":"Hamid","year":"2018","journal-title":"Br J Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","volume":"35","author":"D'Angelo","year":"2017","journal-title":"J Clin Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2019.07.010","article-title":"Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)","volume":"119","author":"Nathan","year":"2019","journal-title":"Eur J Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Investigators pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/jco.2015.33.15_suppl.3012","article-title":"Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL)","volume":"33","author":"Puzanov","year":"2015","journal-title":"J Clin Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"9503","DOI":"10.1200\/JCO.2016.34.15_suppl.9503","article-title":"Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"34","author":"Robert","year":"2016","journal-title":"J Clin Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1","volume":"34","author":"Hodi","year":"2016","journal-title":"J Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/bjd.18425","article-title":"Genetic alterations in primary melanoma in Taiwan","volume":"182","author":"Sheen","year":"2019","journal-title":"Br J Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"6946","DOI":"10.1158\/1078-0432.CCR-17-0070","article-title":"Frequent genetic aberrations in the CDK4 pathway in acral melanoma indicate the potential for CDK4\/6 inhibitors in targeted therapy","volume":"23","author":"Kong","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1111\/cas.14015","article-title":"Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma","volume":"110","author":"Yamazaki","year":"2019","journal-title":"Cancer Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2018.09.025","article-title":"Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: an open-label, single-arm, multicentre phase II study","volume":"105","author":"Namikawa","year":"2018","journal-title":"Eur J Cancer."},{"key":"B29","doi-asserted-by":"publisher","first-page":"ix115","DOI":"10.1093\/annonc\/mdz429.001","article-title":"Response of nivolumab monotherapy in 124 Japanese patients with advanced melanoma: interim analysis of prospective observational study (CREATIVE study)","volume":"30","author":"Yamazaki","year":"2019","journal-title":"Ann Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","article-title":"A Phase Ib study of pembrolizumab as second-line therapy for chinese patients with advanced or metastatic melanoma (KEYNOTE-151)","volume":"12","author":"Si","year":"2019","journal-title":"Transl Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jdermsci.2017.10.009","article-title":"Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: analysis of 60 Japanese patients","volume":"89","author":"Fujisawa","year":"2018","journal-title":"J Dermatol Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00905\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T04:51:17Z","timestamp":1591246277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00905\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":32,"alternative-id":["10.3389\/fonc.2020.00905"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00905","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2020,6,4]]},"article-number":"905"}}